Your shopping cart is currently empty

PPAR agonist4 (Compound 12) is an orally active PPAR agonist that activates PPARα, PPARδ, and PPARγ with EC50 values of 0.7 μM, 0.7 μM, and 1.8 μM, respectively. It also exhibits anti-hepatic fibrosis activity.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | PPAR agonist4 (Compound 12) is an orally active PPAR agonist that activates PPARα, PPARδ, and PPARγ with EC50 values of 0.7 μM, 0.7 μM, and 1.8 μM, respectively. It also exhibits anti-hepatic fibrosis activity. |
| Targets&IC50 | PPARδ:0.7 μM (EC50), PPARα:0.7 μM (EC50), PPARγ:1.8 μM (EC50) |
| In vitro | PPAR agonist 4 (3-10 μM) dose-dependently enhances the expression of PPARα/δ target genes CPT1A, PDK4, and ANGPTL4 in HepG2 cells, as well as PPARγ target genes CD36 and FABP4 in HEK293 cells. |
| In vivo | PPAR agonist 4 (3-30 mg/kg, oral, 3 weeks) effectively reduces collagen deposition and inhibits inflammatory cell infiltration in a mouse model of liver fibrosis induced by CCl4. |
| Formula | C23H28F3N3O3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.